


### IN THE CLAIMS:

The following claims have been amended as indicated below wherein added words are underlined and deleted words are {braced}.

#### **Claims 1-24 (Withdrawn)**

**Claim 25 (Currently amended):** A method of using {the} an ophthalmic device produced {through the method of claim 24} using a polymeric composition produced through the copolymerization of one or more prepolymers produced from one or more prepolymer precursors



---


wherein the R groups may be the same or different saturated C<sub>1-10</sub> hydrocarbon substituents; the R<sub>1</sub> groups may be the same or different C<sub>1-10</sub> alkyl substituents; the R<sub>2</sub> groups may be the same or different selected from the group consisting of C<sub>1-10</sub> alkyl substituents, C<sub>1-10</sub> fluoroalkyl substituents, and C<sub>2-20</sub> alkyl-fluoroalkyl substituents; the R<sub>3</sub> groups may be the same or different C<sub>6-30</sub> aromatic substituents; n is a natural number; and m is a natural number greater than 4

representing the sum of siloxane moieties with randomly differing R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> groups as defined above so as to have a molar ratio of aromatic substituents to alkyl substituents no less than 1:4 such that the prepolymer molecular weight is at least approximately 1000 and refractive index is at least approximately 1.45; and the Z<sub>1</sub> groups may be the same or different selected from the group consisting of –OH and –NH<sub>2</sub>, with one or more aromatic monomers, an alkyl monomers or hydrophilic monomers, comprising:

making an incision in the cornea of an eye; and  
implanting said ophthalmic device.

**Claim 26 (Withdrawn)**

**Claim 27 (Currently amended):** A method of using {the} an ophthalmic device produced {through the method of claim 24 or 26} using one or more prepolymer precursors



wherein the R groups may be the same or different saturated C<sub>1-10</sub> hydrocarbon substituents; the R<sub>1</sub> groups may be the same or different C<sub>1-10</sub> alkyl substituents; the R<sub>2</sub> groups may be the same or different selected from the group consisting of C<sub>1-10</sub> alkyl substituents, C<sub>1-10</sub> fluoroalkyl substituents, and C<sub>2-20</sub> alkyl-fluoroalkyl substituents; the R<sub>3</sub> groups may be the same or different C<sub>6-30</sub> aromatic substituents; n is a natural number; and m is a natural number greater than 4 representing the sum of siloxane moieties with randomly differing R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> groups as defined above so as to have a molar ratio of aromatic substituents to alkyl substituents no less than 1:4 such that the prepolymer molecular weight is at least approximately 1000 and refractive index is at least approximately 1.45; and the Z<sub>1</sub> groups may be the same or different selected from the group consisting of –OH and –NH<sub>2</sub> comprising:

making an incision in the cornea of an eye; and  
implanting said ophthalmic device.

**Claims 28-29 (Withdrawn)**

Should there be any questions regarding this preliminary amendment,  
please feel free to contact the undersigned at (636) 226-3340.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Rita D. Vacca", with a long horizontal flourish extending to the right.

Rita D. Vacca  
Reg. No. 33,624

Correspondence address:  
Rita D. Vacca  
Bausch & Lomb, Inc.  
One Bausch & Lomb Place  
Rochester, New York 14604-2701